ALPINE
10 Nov 2020
Trial Summary
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Acronym:
ALPINE
ACTRN/NCT /ethics:
NCT03734016
Scientific title:
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphocytic Lymphoma
Sponsor / Cooperative group:
BeiGene
Trial & Patient Characteristics
| Cancer Type | Lymphoma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Lymphoma |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | - |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | Dr Stanley Cheung |
| Recruitment Status | Recruiting |